High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma

scientific article published on 26 February 2020

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2147/OTT.S242517
P932PMC publication ID7051865
P698PubMed publication ID32161471

P50authorJianji PanQ82177517
Tianzhu LuQ88826123
Shaojun LinQ90217294
Qiaojuan GuoQ90247416
Jingfeng ZongQ117278902
P2093author name stringYing Su
Yiping Chen
Yunbin Ye
Jieyu Li
Yuhong Zheng
Wansong Lin
P2860cites workHallmarks of Cancer: The Next GenerationQ22252312
The blockade of immune checkpoints in cancer immunotherapyQ27860852
Advances in targeting cell surface signalling molecules for immune modulationQ36973787
Nasopharyngeal carcinoma: current management, future directions and dental implicationsQ37025339
Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapyQ37141483
Host-tumor interactions in nasopharyngeal carcinomasQ37976234
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.Q38583301
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.Q38954827
Epstein-Barr virus infection and nasopharyngeal carcinomaQ40046633
Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patientsQ47256356
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.Q49309172
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.Q50993649
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.Q53097632
The Microenvironment in Epstein-Barr Virus-Associated Malignancies.Q54236409
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 responseQ59070397
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesQ60142201
Immune checkpoint inhibitors: recent progress and potential biomarkersQ60302456
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trialQ60685639
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.Q64925763
Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary studyQ90418185
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patientsQ91004899
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian CancerQ91083851
Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA markerQ91325361
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trialsQ91433225
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapyQ91520697
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patientsQ91553095
Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomasQ91914786
Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancerQ92322348
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of ImmunotherapyQ92625292
Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsQ93129314
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P304page(s)1757-1765
P577publication date2020-02-26
P1433published inOncoTargets and TherapyQ7092081
P1476titleHigh Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
P478volume13

Reverse relations

Q98288422TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolismcites workP2860

Search more.